SMEs (small and medium-sized enterprises) see benefit from UK Patents Bill:
This article was originally published in Clinica
The UK Patents Bill was passed by parliament on July 14, at the third reading. It incorporates a clause (amending section 106 of the Patents Act 1977) that aims to "make a small additional improvement to the framework for enforcement of patent rights" and an amendment which seek to address the concerns particularly of small and medium-sized enterprises (SMEs). The changes "aim to help SMEs in appropriate circumstances where they face litigation in the courts", taking into account the need for the framework to be "accessible to an SME patent holder, but which is also fair to a party against whom enforcement action may be taken, [which] may be another SME".
You may also be interested in...
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.
Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.
Kline & Company’s worst-case scenario – which it says is looking more and more likely – has the US cosmetics and personal-care market declining by as much as 8.1% in 2020. However, Kline, Mintel and other market intelligence firms say there are opportunities available to companies struggling to weather the COVID-19 storm.